VALCHLOR® (mechlorethamine) gel is a prescription medicine used on the skin (topical) to treat people with Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) who have received previous skin treatment. It is not known if VALCHLOR is safe and effective in children.

Understanding MF-CTCL

What is MF-CTCL?

MF-CTCL, which stands for mycosis–fungoides type cutaneous T-cell lymphoma, is the most common cutaneous T-cell lymphoma (CTCL). The disease is typically slow growing and may be mistaken for other inflammatory skin conditions such as eczema or psoriasis, which VALCHLOR does not treat. MF-CTCL may be present for years or even decades before it's diagnosed.

Getting a CLEAR picture of Stage IA/IB MF-CTCL

You are not alone. Stage IA/IB MF-CTCL is thought to affect 16,000 to 20,000 patients in the United States. MF-CTCL is a progressive disease with distinct stages, each of which has a different treatment approach.

Although MF-CTCL can occur anywhere on your body, it often appears on skin that is covered by clothing and unexposed to sunlight.

Symptoms of MF-CTCL: what it may look like

Your stage of MF-CTCL is based on how much of your body has red patches of skin and/or scaly raised scabs called plaques.

Artistic rendition of Stage IA/IB MF-CTCL as Patches

Stage IA/Patch

Artistic rendition of Stage IA/IB MF-CTCL as Plaques

Stage IB/Plaque

Artistic rendition of Stage IA/IB MF-CTCL as Hypopigmentation

Stage IA/IB/Hypopigmentation

Actual patient examples.

Stage IA: patches and/or plaques cover up to 10% of the skin

Stage IB: patches and/or plaques cover 10% to 79% of the skin

  • Most patients have Stage IA/IB MF-CTCL for several years
  • In some cases, it can progress to later-stage disease